Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for Long-Term psoriatic arthritis control

NCT ID NCT04009499

Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 3 times

Summary

This study looked at the long-term safety and effectiveness of bimekizumab in adults with active psoriatic arthritis. Over 1,100 people who completed earlier studies received the drug and were monitored for side effects and disease symptoms. The goal was to see if bimekizumab remains safe and helpful over time for managing this chronic condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,131 people

The number who actually took part.

Started

Aug 2019

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * In the opinion of the Investigator, the subject is expected to benefit from participation in this Open-Label Extension study * Subject completed PA0010 \[NCT03895203\] or PA0011 \[NCT03896581\] without meeting any withdrawal criteria * Female subjects must be postmenopausal, permanently sterilized or willing to use a highly effective method of contraception Exclusion Criteria: * Female subjects who plan to become pregnant during the study or within 20 weeks following the last dose of investigational medicinal product (IMP) * Subjects who meet any withdrawal criteria in PA0010 or PA0011. For any subject with an ongoing serious adverse event (SAE), or a history of serious infections (including hospitalizations) in the feeder studies, the Medical Monitor must be consulted prior to the subject's entry into PA0012, although the decision to enroll the subject remains with the Investigator * Subject has a positive or 2 indeterminate interferon gamma release assays (IGRAs) in one of the feeder studies, unless appropriately evaluated and treated

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriatic arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriatic arthritis

Contacts and locations

Locations

  • Pa0012 20001

    Saint Petersburg, Russia

  • Pa0012 20002

    Moscow, Russia

  • Pa0012 20003

    Saint Petersburg, Russia

  • Pa0012 20004

    Saint Petersburg, Russia

  • Pa0012 20005

    Moscow, Russia

  • Pa0012 20006

    Vladimir, Russia

  • Pa0012 20007

    Saratov, Russia

  • Pa0012 20008

    Yaroslavl, Russia

  • Pa0012 20009

    Saint Petersburg, Russia

  • Pa0012 20010

    Moscow, Russia

  • Pa0012 20012

    Ryazan, Russia

  • Pa0012 20013

    Petrozavodsk, Russia

  • Pa0012 20014

    Ulyanovsk, Russia

  • Pa0012 20015

    Yaroslavl, Russia

  • Pa0012 20016

    Ryazan, Russia

  • Pa0012 20017

    Moscow, Russia

  • Pa0012 20030

    Chūōku, Japan

  • Pa0012 20031

    Sapporo, Japan

  • Pa0012 20032

    Suita, Japan

  • Pa0012 20033

    Nagoya, Japan

  • Pa0012 20035

    Bunkyō City, Japan

  • Pa0012 20036

    Kawachi-Nagano, Japan

  • Pa0012 20041

    Osaka, Japan

  • Pa0012 20042

    Sasebo, Japan

  • Pa0012 20043

    Itabashi-ku, Japan

  • Pa0012 20044

    Minatoku, Japan

  • Pa0012 20045

    Kita-gun, Japan

  • Pa0012 20046

    Osaka, Japan

  • Pa0012 20048

    Saitama, Japan

  • Pa0012 20049

    Kitakyushu, Japan

  • Pa0012 20083

    Saint Petersburg, Russia

  • Pa0012 30002

    Clayton, Australia

  • Pa0012 30003

    Maroochydore, Australia

  • Pa0012 30005

    Camberwell, Australia

  • Pa0012 30006

    Woodville South, Australia

  • Pa0012 30007

    Victoria Park, Australia

  • Pa0012 30008

    Hobart, Australia

  • Pa0012 40002

    Leuven, Belgium

  • Pa0012 40003

    Genk, Belgium

  • Pa0012 40009

    Pardubice, Czechia

  • Pa0012 40010

    Uherské Hradiště, Czechia

  • Pa0012 40012

    Zlín, Czechia

  • Pa0012 40013

    Prague, Czechia

  • Pa0012 40014

    Prague, Czechia

  • Pa0012 40015

    Prague, Czechia

  • Pa0012 40019

    Paris, France

  • Pa0012 40023

    Erlangen, Germany

  • Pa0012 40025

    Berlin, Germany

  • Pa0012 40026

    Ratingen, Germany

  • Pa0012 40027

    Herne, Germany

  • Pa0012 40029

    Hamburg, Germany

  • Pa0012 40030

    Eger, Hungary

  • Pa0012 40032

    Debrecen, Hungary

  • Pa0012 40033

    Székesfehérvár, Hungary

  • Pa0012 40037

    Lublin, Poland

  • Pa0012 40038

    Elblag, Poland

  • Pa0012 40039

    Wroclaw, Poland

  • Pa0012 40041

    Warsaw, Poland

  • Pa0012 40042

    Krakow, Poland

  • Pa0012 40043

    Wroclaw, Poland

  • Pa0012 40044

    Poznan, Poland

  • Pa0012 40045

    A Coruña, Spain

  • Pa0012 40049

    Seville, Spain

  • Pa0012 40059

    Mons, Belgium

  • Pa0012 40061

    Brno, Czechia

  • Pa0012 40062

    Moravska Ostrava A Privoz, Czechia

  • Pa0012 40063

    Prague, Czechia

  • Pa0012 40065

    Brno, Czechia

  • Pa0012 40066

    Prague, Czechia

  • Pa0012 40068

    Chambray-lès-Tours, France

  • Pa0012 40071

    Hamburg, Germany

  • Pa0012 40074

    Bad Doberan, Germany

  • Pa0012 40076

    Cottbus, Germany

  • Pa0012 40078

    Leipzig, Germany

  • Pa0012 40079

    Szentes, Hungary

  • Pa0012 40081

    Budapest, Hungary

  • Pa0012 40082

    Kistarcsa, Hungary

  • Pa0012 40083

    Budapest, Hungary

  • Pa0012 40084

    Catania, Italy

  • Pa0012 40086

    Reggio Emilia, Italy

  • Pa0012 40087

    Milan, Italy

  • Pa0012 40088

    Elblag, Poland

  • Pa0012 40090

    Poznan, Poland

  • Pa0012 40091

    Nowa Sól, Poland

  • Pa0012 40092

    Krakow, Poland

  • Pa0012 40093

    Bialystok, Poland

  • Pa0012 40094

    Warsaw, Poland

  • Pa0012 40095

    Wroclaw, Poland

  • Pa0012 40096

    Gdynia, Poland

  • Pa0012 40097

    Warsaw, Poland

  • Pa0012 40098

    Warsaw, Poland

  • Pa0012 40099

    Vigo, Spain

  • Pa0012 40101

    Sabadell, Spain

  • Pa0012 40102

    Málaga, Spain

  • Pa0012 40104

    Santiago de Compostela, Spain

  • Pa0012 40105

    Córdoba, Spain

  • Pa0012 40106

    Seville, Spain

  • Pa0012 40107

    Wolverhampton, United Kingdom

  • Pa0012 40109

    Oxford, United Kingdom

  • Pa0012 40116

    Peterborough, United Kingdom

  • Pa0012 40117

    Frankfurt am Main, Germany

  • Pa0012 40118

    Warsaw, Poland

  • Pa0012 40119

    Bydgoszcz, Poland

  • Pa0012 50001

    Jackson, Tennessee, 38305, United States

  • Pa0012 50002

    Austin, Texas, 78731, United States

  • Pa0012 50005

    Freehold, New Jersey, 07728, United States

  • Pa0012 50006

    Wyomissing, Pennsylvania, 19610, United States

  • Pa0012 50007

    Orangeburg, South Carolina, 29118, United States

  • Pa0012 50008

    Johnston, Rhode Island, 02919, United States

  • Pa0012 50009

    Waco, Texas, 76710, United States

  • Pa0012 50010

    Brooklyn, New York, 11201, United States

  • Pa0012 50011

    New York, New York, 10029, United States

  • Pa0012 50012

    Memphis, Tennessee, 38119-5214, United States

  • Pa0012 50015

    Hagerstown, Maryland, 21740, United States

  • Pa0012 50016

    St Louis, Missouri, 63141, United States

  • Pa0012 50017

    Phoenix, Arizona, 85037, United States

  • Pa0012 50019

    Lansing, Michigan, 48911, United States

  • Pa0012 50020

    Duncansville, Pennsylvania, 16635, United States

  • Pa0012 50023

    Baton Rouge, Louisiana, 70836, United States

  • Pa0012 50024

    Boise, Idaho, 83702, United States

  • Pa0012 50028

    Lexington, Kentucky, 40504, United States

  • Pa0012 50029

    Albuquerque, New Mexico, 87102, United States

  • Pa0012 50031

    Winston-Salem, North Carolina, 27104, United States

  • Pa0012 50033

    Palm Harbor, Florida, 34684, United States

  • Pa0012 50034

    Rochester, New York, 14642, United States

  • Pa0012 50035

    San Diego, California, 92128, United States

  • Pa0012 50036

    Mesquite, Texas, 75150, United States

  • Pa0012 50037

    Tampa, Florida, 33613, United States

  • Pa0012 50039

    Atlanta, Georgia, 30342, United States

  • Pa0012 50040

    Vandalia, Ohio, 45377, United States

  • Pa0012 50041

    Québec, Canada

  • Pa0012 50042

    Rimouski, Canada

  • Pa0012 50043

    Sydney, Canada

  • Pa0012 50044

    Trois-Rivières, Canada

  • Pa0012 50047

    Boston, Massachusetts, 02115-5817, United States

  • Pa0012 50049

    Corpus Christi, Texas, 78404, United States

  • Pa0012 50050

    Beckley, West Virginia, 25801, United States

  • Pa0012 50125

    Charlotte, North Carolina, 28211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.